Skip to main content
    U

    Utah Medical Products Inc (UTMD)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $72.36
    +0.39 (+0.54%)

    Market Cap: $204.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Utah Medical Products Inc (UTMD) Financials: Revenue, Profit and Cash Flow

    Updated Oct 22, 2026. Financial statements from company filings, amounts in US dollars.

    Utah Medical Products reported revenue of $38.52M for the fiscal year ended Dec 31, 2025, down 5.8% from the year before. That year, net income was $11.29M with a net margin of 29.3%, operating cash flow was $14.69M and free cash flow was $14.32M. The quarter ended Sep 30, 2026 had revenue of $8.62M and net income of $2.79M.

    Revenue and Margins

    The operating margin was 29.6% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue fell from $39.30M, a compound annual decline of 0.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$38.52M-5.8%57.1%29.6%29.3%
    Dec 2024$40.90M-18.6%59.0%33.2%33.9%
    Dec 2023$50.22M-3.9%59.8%33.4%33.1%
    Dec 2022$52.28M+6.6%61.6%37.9%31.5%
    Dec 2021$49.05M+16.3%63.0%38.5%30.1%
    Dec 2020$42.18M-10.1%60.6%32.5%25.6%
    Dec 2019$46.90M+11.7%62.8%37.6%31.4%
    Dec 2018$42.00M+1.4%62.6%44.5%44.2%
    Dec 2017$41.41M+5.4%63.7%45.9%20.5%
    Dec 2016$39.30MN/A60.3%41.2%30.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 18.6% from the year before. In the quarter ended Sep 2026, net income rose 6.1% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$38.52M$40.90M$50.22M$52.28M$49.05M$42.18M$46.90M$42.00M$41.41M$39.30M
    Cost of revenue$16.52M$16.76M$20.19M$20.09M$18.14M$16.63M$17.44M$15.69M$15.02M$15.61M
    Gross profit$22.00M$24.14M$30.04M$32.20M$30.92M$25.55M$29.47M$26.31M$26.39M$23.69M
    Research and development$668.00K$813.00K$560.00K$493.00K$526.00K$486.00K$483.00K$454.00K$447.00K$475.00K
    Operating income$11.40M$13.59M$16.78M$19.79M$18.88M$13.71M$17.63M$18.70M$19.01M$16.19M
    Net income$11.29M$13.87M$16.64M$16.47M$14.79M$10.80M$14.73M$18.55M$8.51M$12.13M
    EBITDA$14.29M$16.27M$23.40M$27.06M$26.16M$20.92M$24.51M$22.09M$21.75M$19.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$8.62M$8.53M$8.72M$9.04M$9.81M$9.95M$9.71M$9.16M$10.01M$10.40M$11.34M$12.33M
    Gross profit$4.84M$4.76M$5.28M$4.73M$5.60M$5.59M$5.54M$5.32M$5.80M$6.25M$6.77M$7.10M
    Operating income$2.79M$2.65M$2.56M$2.44M$2.61M$3.20M$3.15M$2.93M$3.34M$3.44M$3.88M$3.94M
    Net income$2.79M$2.69M$2.60M$2.56M$2.63M$3.05M$3.04M$2.90M$3.56M$3.45M$3.96M$4.29M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded long-term debt of $225.00K by $85.53M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$122.54M$122.54M$135.46M$123.87M$115.64M$111.75M$109.79M$99.77M$92.75M$76.19M
    Current assets$97.74M$96.33M$106.27M$89.92M$73.16M$62.26M$54.89M$60.90M$49.19M$34.47M
    Cash and equivalents$85.76M$82.98M$92.87M$75.05M$60.97M$51.59M$42.79M$51.11M$39.88M$26.30M
    Total liabilities$3.27M$5.11M$7.14M$9.62M$8.50M$8.92M$8.69M$10.78M$14.62M$6.95M
    Short-term debtN/A$56.00K$47.00K$54.00K$52.00K$41.00K$38.00KN/AN/AN/A
    Long-term debt$225.00K$282.00K$295.00KN/AN/AN/AN/AN/A$0$0
    Shareholder equity$119.27M$117.43M$128.31M$114.25M$107.14M$102.82M$101.09M$88.99M$78.12M$69.24M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$128.50M$124.57M$124.38M$122.54M$121.97M$120.80M$122.52M$122.54M$129.69M$130.03M$135.44M$135.46M
    Total liabilities$5.22M$2.54M$4.01M$3.27M$3.72M$3.27M$5.47M$5.11M$5.50M$5.98M$7.70M$7.14M
    Cash and equivalents$85.20M$87.53M$87.41M$85.76M$84.27M$82.18M$83.33M$82.98M$88.45M$89.22M$93.81M$92.87M
    Shareholder equity$123.28M$122.03M$120.37M$119.27M$118.25M$117.53M$117.05M$117.43M$124.20M$124.05M$127.74M$128.31M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 97.5% of operating cash flow. Dividends and share repurchases together came to 86.2% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$14.69M$14.83M$22.28M$21.15M$21.20M$20.14M$17.06M$16.83M$16.91M$14.53M
    Capital expenditures$371.00K$230.00K$639.00K$809.00K$552.00K$860.00K$540.00K$402.00K$1.60M$3.29M
    Free cash flow$14.32M$14.60M$21.64M$20.34M$20.65M$19.28M$16.52M$16.43M$15.31M$11.23M
    Dividends paid$3.98M$4.26M$4.28M$3.16M$11.46M$4.12M$4.11M$4.03M$2.96M$3.92M
    Share repurchases$8.36M$19.97M$0$2.50M$0$6.98M$398.00K$1.21M$0N/A
    Investing cash flow-$371.00K-$208.00K-$639.00K-$818.00K-$552.00K-$860.00K-$21.54M$534.00K-$1.60M-$3.30M
    Financing cash flow-$12.34M-$23.84M-$4.17M-$5.48M-$10.90M-$10.73M-$4.23M-$4.78M-$2.65M-$6.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$3.50M$1.38M$3.11M$3.48M$3.88M$2.87M$4.46M$2.94M$3.86M$2.76M$5.28M$5.33M
    Capital expenditures$236.00K$134.00K$130.00K$109.00K$27.00K$51.00K$184.00K$9.00K$89.00K$110.00K$22.00K$90.00K
    Free cash flow$3.26M$1.25M$2.98M$3.37M$3.85M$2.82M$4.28M$2.93M$3.77M$2.65M$5.25M$5.24M
    Last 12 quarters

    Frequently Asked Questions About UTMD

    What is Utah Medical Products' annual revenue?

    Utah Medical Products reported revenue of $38.52M for the fiscal year ended Dec 31, 2025.

    How fast is Utah Medical Products' revenue growing?

    Revenue was down 5.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -9.7%.

    Is Utah Medical Products profitable?

    Yes. Utah Medical Products reported net income of $11.29M for the fiscal year ended Dec 31, 2025, with a net margin of 29.3%.

    How much free cash flow does UTMD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $14.69M minus capital expenditures of $371.00K produced free cash flow of $14.32M.

    How much debt does Utah Medical Products have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $225.00K and cash and equivalents of $85.76M.